key: cord-0994995-vjhgl6y3
authors: Favorskaya, Irina A.; Shcheblyakov, Dmitry V.; Esmagambetov, Ilias B.; Dolzhikova, Inna V.; Alekseeva, Irina A.; Korobkova, Anastasia I.; Voronina, Daria V.; Ryabova, Ekaterina I.; Derkaev, Artem A.; Kovyrshina, Anna V.; Iliukhina, Anna A.; Botikov, Andrey G.; Voronina, Olga L.; Egorova, Daria A.; Zubkova, Olga V.; Ryzhova, Natalia N.; Aksenova, Ekaterina I.; Kunda, Marina S.; Logunov, Denis Y.; Naroditsky, Boris S.; Gintsburg, Alexandr L.
title: Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern
date: 2021-11-24
journal: bioRxiv
DOI: 10.1101/2021.11.24.469842
sha: ac52ace021610f09aca95b03a768763079fc69b4
doc_id: 994995
cord_uid: vjhgl6y3

Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma and Delta variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern.

Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of 23 SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some 24

antibody-based therapies. The development of potent antibodies with a broad spectrum of 25 neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that 26 specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the 27 selected antibodies exhibiting most robust neutralization potency were used to generate dimeric 28 molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing 29 activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 30 variant of concern, including Alpha, Beta, Gamma and Delta variants. This heterodimeric molecule 31 could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of 32 concern. 33 34

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 36 2), has resulted in over 250 million of infections and over 5 million deaths worldwide (November 37 2021, WHO). These numbers are still rising and COVID-19 disease remains a great challenge to 38

public health system. The development of safe and effective treatment together with vaccination is a 39 highly important goal for scientists and health care professionals over the world. 40

One of the approaches to the development of an effective therapeutic agent is the isolation of 41 monoclonal antibodies that efficiently neutralize SARS-CoV-2 virus. Currently, several monoclonal 42 antibodies already received emergency use authorization for COVID-19 treatment and post-exposure 43

prophylaxis. These antibodies are bamlanivimab plus etesevimab, casirivimab plus imdevimab and 44

sotrovimab (1) (2) (3) . 45

Along with conventional antibodies, camelid single-domain antibodies (also called nanobodies or 46

VHHs) are promising candidates for the development of antibody-based therapies (4, 5). Camelids 47 have unique heavy-chain antibodies that are devoid of light chains (6). Nanobodies are the minimal 48

antigen-binding domains of these heavy-chain antibodies. They have several advantages, including 49 the ability to recognize epitopes that are not accessible to conventional antibodies, increased stability 50 of nanobodies, simplicity of generation of multivalent forms and low cost bacterial production (7). 51

Currently, several nanobodies to SARS-COV-2 have been isolated showing neutralizing activity in in 52

vitro and in vivo studies, which confirms their promising potential as therapeutic agents (8) (9) (10) (11) (12) (13) (14) . 53

The evolution of SARS-CoV-2 virus has resulted in emergence of virus variants that have become 54 more transmissible and less sensitive to neutralizing antibodies. The spread of these new virus 55 variants has reduced the efficacy of vaccines and some therapeutic antibodies. The list of these 56 variants of concern (VOCs) consist of B. , including K417N/T, L452R, T478K, E484K and N501Y  59 substitutions (15, 16) . In this regard, it became necessary to isolate antibodies, the neutralizing 60 activity of which will not be affected due to observed mutations, therefore, these antibodies or their 61 cocktails will retain activity against each of VOCs. 62

Here we identified and characterized a panel of single-domain antibodies isolated from immune VHH 63 library that specifically bind RBD of S glycoprotein. We assessed the neutralizing activity of the 64 isolated antibodies in a microneutralization assay with live SARS-CoV-2 and selected three most 65 potent antibodies. To increase the therapeutic potential, these clones were modified to homodimeric 66 and heterodimeric forms, and the neutralizing activity against SARS-CoV-2 VOCs was investigated. 67

The most potent heterodimeric form, P2C5-P5F8, exhibited activity against all tested virus variants at 68 low concentration. These results indicate that P2C5-P5F8 heterodimer is a promising candidate for 69 further research to develop COVID-19 antibody-based therapy. 70

To identify SARS-CoV-2 neutralizing single-domain antibodies we immunized one Bactrian camel 72

with SARS-CoV-2 RBD. The recombinant RBD protein was previously produced in CHO-S cells 73 and purified. Immunization was performed using five sequential injections ( Fig 1A) . Blood was 74 collected 5 days after final immunization and the serum RBD-specific antibodies titer was detected 75 by ELISA. Post-immunization serum demonstrated potent binding to SARS-CoV-2 RBD with titer 76 more than 1/200 000 (Fig 1B) . The neutralizing activity of antibodies in the immunized serum was 77 measured by the microneutralization assay using live SARS-CoV-2 B.1.1.1, the neutralizing 78 antibodies titer was 1/1280. 79

To isolate monoclonal RBD-specific nanobodies, we constructed a VHH phage display library by 80 cloning VHH sequences from B cells of immunized camel into a phagmid vector. We performed one 81 round of phage display followed by ELISA-based screening of individual clones to identify RBD-82 specific binders. 83

We used monoclonal phage-ELISA together with monoclonal ELISA to identify RBD binders with 84 high expression levels and high solubility. A total of 212 clones showing positive phage-ELISA and 85

ELISA signals were selected for sequencing (Fig 1C) , which lead to the identification of 39 unique 86 clones of nanobodies. After sequence alignment and phylogenetic analysis we selected 16 antibodies 87 with highly diverse sequences for further research (Fig 1D) . These nanobodies were expressed and 88 purified, and the RBD binding activity of each antibody was analyzed by ELISA. We confirmed the 89 binding of 14 clones with ELISA EC50 values ranged from 1.1 to 313.3 nM (Fig 2A) . Most of the 90 antibodies (13 out of 14) displayed strong positive signals with EC50 below 22 nM. 91

To examine the capacity of selected RBD binders to neutralize live SARS-CoV-2 virus we performed 92 a microneutralization assay with inhibition of the cytopathic effect of virus as a marker of 93 neutralization. We found that 10 of 14 nanobodies efficiently neutralized SARS-CoV-2 virus 94 (B.1.1.1) at concentrations ranging from 12 nM to 1540 nM (Fig 2A) . The three most potent 95 antibodies were P2C5, P2G1 and P5F8, which completely inhibited the cytopathic effect of the virus 96 at 24 nM, 12 nM and 48 nM, respectively. 97

We investigated the binding kinetics of P2C5, P2G1 and P5F8 neutralizing nanobodies via surface 98 plasmon resonance (SPR). All antibodies tested bound RBD with high affinity, dissociation constants 99 (K D ) were 3.97 nM, 5.36 nM and 1.94 nM for P2C5, P2G1 and P5F8, respectively ( Fig 2C) . 100

Since the capacity of an antibody to neutralize SARS-CoV-2 virus is frequently associated with 101 blocking the interaction between S glycoprotein and ACE2 receptor, we analyzed the ability of 102 isolated nanobodies to block the RBD binding to ACE2 by competitive ELISA (Fig 2B) . We 103 revealed a decrease in ELISA signal for most of neutralizing nanobodies indicating antibodies 104 competition with ACE2 for RBD binding. We observed that one of the most potent neutralizing 105 antibodies, P2C5, blocked the ACE2-RBD interaction with an inhibition rate greater than 90% at 0.5 106 μg/ml. 107

In order to improve the antiviral property of antibodies we produced homodimer and heterodimer 108 forms of P2C5, P2G1 and P5F8 clones. Monomers were fused using a flexible GS-linker (Gly4Ser) 4 109 for dimerization. The binding of generated dimeric molecules to the recombinant RBD protein was 110 confirmed by ELISA. Analysis of the neutralization capacity in the microneutralization assay 111 revealed a pronounced improvement in the neutralizing activity of several dimeric forms (Table 1) . 112

Notable, P2C5 homodimer inhibited cytopathic effect of the virus at 89 pM, thus the homodimer 113 activity increased more than 200-fold compared to the monomer activity. We also observed that 114 P2C5-P5F8 heterodimer form was up to 100 times more active than the monomeric forms, this 115 molecule exhibited neutralization activity at 178 pM. 116

With the emergence and spread of new variants of SARS-CoV-2 with increased transmissibility and 117 reduced neutralization by antibodies it became necessary to isolate antibodies with a broad spectrum 118 of neutralizing activity. We assessed the neutralizing activity of isolated antibodies against variants 119 of concern (VOCs), including B. activity against each of the tested VOCs and was a promising candidate for further investigations as a 129 potential therapeutic agent. 130

The SARS-CoV-2 virus gave rise to ongoing pandemic, which continues to claim lives and poses a 132 threat to public health. Along with vaccination to prevent COVID-19, therapeutic antiviral agents are 133 urgently needed to treat the infection. 134

One of the promising approaches for the viral infection treatment is an antibody-based therapy. 135

Antibodies administration approved for immunoprophylaxis and treatment of viral infections caused 136 by respiratory syncytial virus and ebolavirus (17, 18). Today, several monoclonal antibodies are 137 already in use for COVID-19 treatment (bamlanivimab plus etesevimab, casirivimab plus imdevimab 138 and sotrovimab). It was shown that the administration of these antibodies to nonhospitalized patients 139 with symptomatic COVID-19 and risk factors for disease progression reduced the risk of 140 hospitalization and death (1) (2) (3) . 141

In addition to conventional antibodies, single-domain antibodies or nanobodies from camelid heavy-142 chain antibodies are being actively investigated as a potential therapeutic agent with a number of 143

advantages. The small size and single-domain nature of nanobodies allow them to bind epitopes that 144

are not available for conventional antibodies, in particular concave epitopes such as grooves and 145 clefts (19-21). Nanobodies show strong binding affinities and also are highly stable across wide 146 range of temperatures and pH (22). The production of nanobodies in bacteria is less expensive than 147 classical antibody production. All this allows the use of single-domain antibodies for many of 148 applications, including research, diagnostics and therapy (5, 7). 149

The main mechanism of virus-neutralizing activity of antibodies is associated with the prevention of 150 viral entry into host cells. The entry of SARS-CoV-2 virus occurs after the interaction of S 151 glycoprotein with cell receptor angiotensin-converting enzyme 2 (ACE2). Therefore, S glycoprotein, 152

in particular its receptor-binding domain (RBD), is an attractive target for the development of 153 neutralizing antibodies. 154

In our work, we immunized a Bactrian camel with the recombinant RBD protein for following 155 isolation of effective neutralizing antibodies against SARS-CoV-2 virus. We generated a VHH phage 156 display library and selected a panel of RBD-specific nanobodies. Using an in vitro 157 microneutralization assay we identified three clones (P2C5, P5F8 and P2G1) of the most potent 158

antibodies that completely inhibited the cytopathic effect of SARS-CoV-2 virus at minimal 159 concentrations from 12 nM to 48 nM. 160

At the next stage, to enhance the neutralization potential of isolated nanobodies we generated 161 homodimeric and heterodimeric forms of the most active antibodies. It was previously shown that 162 multivalent forms of nanobodies are characterized by increased functionality by improving antigen-163 binding through avidity effect (23). For example, the dimeric form of anti-TNF VHH was up to 500 164 times more active than the monovalent form in rheumatoid arthritis model in vivo (24) Global. 208

The RBD nucleotide sequence of SARS-CoV-2 Wuhan-Hu-1 isolate (Genbank accession number 210 MN908947, from 319 to 545 aa) was synthesized (Evrogen, Russia) and cloned into the pCEP4 211 mammalian expression vector (Thermo Fisher Scientific, USA). The signal peptide of alkaline 212 phosphatase SEAP was inserted before RBD coding sequence, the His tag was fused to the end of the 213 sequence. The obtained recombinant vector was transfected into CHO-S cells using CHOgro High 214

Yield Expression System (Mirus Bio, USA). The culture supernatant containing the RBD protein was 215 harvested after 10 days, the recombinant RBD protein was purified by IMAC using an AKTA start 216 system (Cytiva, USA) and a HisTrap column (Cytiva, USA). The protein expression and purity was 217 confirmed with SDS-PAGE. 218

Bactrian camel was immunized with recombinant SARS-CoV-2 RBD protein at a dose of 100 μg 220 with complete Freund`s adjuvant subcutaneously followed by four booster immunizations with 100 221 μg RBD with incomplete Freund`s adjuvant. The interval between the first and second injections was 222 14 days; the intervals between all subsequent injections were 10 days. Before immunization, a small 223 blood sample (5 ml) was collected as a control. 50 ml blood was collected 5 days after the last 224 immunization and was used for peripheral blood mononuclear cells (PBMC) isolation and VHH 225 phage display library construction. 226

The library construction was performed as described earlier (25) was calculated by comparing the signals in the sample and the negative control wells. 272

Phagmids encoding the sequences of the selected nanobodies were transformed into BL21 cells 274 (NEB, USA) for expression and purification. The cells were cultured in 100 ml 2xYT (containing 275 100 μg/ml ampicillin) overnight at 30 ᵒC. The cells were harvested by centrifugation and lysed by a 276

BugBuster Protein Extraction Reagent (Novagen, USA). Nanobodies were purified by IMAC using 277 an AKTA start system and a HisTrap column, dialyzed against PBS and sterile filtered. Protein 278 expression and purity was confirmed with SDS-PAGE. 279

Nanobodies were serial two-fold diluted starting from 20 μg/ml to 1.2 ng/ml in complete Dulbecco`s 281 modified Eagle medium (DMEM) supplemented with 2% heat-inactivated fetal bovine serum (HI-282 FBS). Triplicates of each dilution were mixed with 100 50% tissue culture infectious doses (TCID50)  283 of SARS-CoV-2 and incubated at 37 ᵒC for 1 h. After incubation samples were added to a monolayer 284 of Vero E6 cells and incubated in a 5% CO 2 incubator at 37 ᵒC for 96-120 h. The cytopathic effect 285 (CPE) of the virus was assessed visually. The minimal neutralizing concentration was defined as the 286 lowest antibody concentration (highest antibody dilution) that completely inhibited CPE of the virus 287 in two or three of the three replicable wells. 288

The following SARS-CoV-2 strains were used in the assay: B. 1.1.1, B.1.1.7, B.1.351 All experiments were performed in a Biosafety Level 3 facility (BSL-3) . 291

The affinity of nanobodies was measured by surface plasmon resonance (Biacore 3000, GE 293

Healthcare Bio-Sciences AB, Sweden). Recombinant RBD protein at a concentration 20 μg/ml in 10 294 mM acetate buffer (pH 4.5) was immobilized on the surface of a CM5 sensor chip using a Amine 295

Coupling Kit (GE Healthcare Bio-Sciences AB, Sweden). VHHs were serial 4-fold diluted from 417 296 nM to 0 nM and flowed over the captured RBD surface at 15 μl/min for 3 minutes. Dissociation time 297 was 10 minutes. Working buffer was HBS-EP (0.01 M HEPES pH 7.4, 0.15 M NaCl, 2 mM EDTA, 298 0.005% v/v Surfactant P20). After each injection, the chip surface was regenerated with 10 mM Tris-299

HCl, pH 1.5 for 40 s at a flow rate 30 μl/min. Calculations were performed using the BIAEvaluation 300 software (GE Healthcare Bio-Sciences AB, Sweden). 301

Homodimeric and heterodimeric forms of nanobodies were generated using two rounds of PCR 303 followed by cloning PCR products into a pHEN1 vector. VHHs in dimeric forms were fused by GS-304 linker (Gly4Ser) 4 . In the first round of PCR, VHH monomers were amplified using Q5 High-fidelity 305 DNA polymerase (NEB, UK) and the primers listed in aLRT) (36) . The WAG substitution model was selected assuming an estimated proportion of 324 invariant sites (of 0.000) and 4 gamma-distributed rate categories to account for rate heterogeneity 325 across sites. The gamma shape parameter was estimated directly from the data (gamma=0.448). 326

Reliability for internal branch was assessed using the aLRT test (SH-Like) (37). Graphical 327 representation and edition of the phylogenetic tree were performed with MEGA X (34). 328 

Bamlanivimab plus 346 Etesevimab in Mild or Moderate Covid-19

Early Treatment 349 for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Antibody Combination and Outcomes in Outpatients with Covid-19

Perspective on therapeutic and 355 diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)

The Therapeutic Potential of Nanobodies

Single domain camel antibodies: current status

Nanobodies: natural single-domain antibodies

Development of 364 humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2

A potent SARS-CoV-2 367 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of 368 COVID-19

Development of multivalent nanobodies 370 blocking SARS-CoV-2 infection by targeting RBD of spike protein

Nanobody cocktails 373 potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

An ultrapotent synthetic 376 nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

Versatile and multivalent 379 nanobodies efficiently neutralize SARS-CoV-2

Multimeric nanobodies from 382 camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants. bioRxiv (2021)

CoV-2 variants, spike mutations and immune escape

Defining variant-resistant 388 epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

First Approval

Passive 393 Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now

Molecular basis for the 396 preferential cleft recognition by dromedary heavy-chain antibodies

Applications of Nanobodies

Structural Basis of Epitope Recognition by 401 Heavy-Chain Camelid Antibodies

A simple, fast, and accurate algorithm to estimate large phylogenies by 447 maximum likelihood

Approximate likelihood-ratio test for branches: A fast, accurate, and 449 powerful alternative

Molecular analysis of heavy chain-only antibodies of 451 Camelus bactrianus

immunized with 100 mcg RBD subcutaneously (with complete Freund`s adjuvant), followed by four 456 consecutive immunization with 100 mcg RBD subcutaneously (with incomplete Freund`s adjuvant). 457Blood samples were collected before immunization and five days after the last immunization. (B)  458 RBD-specific antibodies in camel serum before and after immunization, detected by ELISA. The 459 assay reveals a strong positive RBD-specific serological activity 5 days after the last immunization.